Squamous cell carcinoma of lung
Definition
A tumour
arising from bronchial epithelium showing keratinisation or
intercellular bridges.
Epidemiology
Squamous
cell carcinoma accounts for about 45% of primary lung carcinomas in
men, 25% in women. More than 90% of squamous cell carcinomas
of lung occur in cigarette smokers.
Squamous cell
carcinomas can be subdivided into central and peripheral. The
peripheral tumours present in older patients, at a lower stage, with
less lymph node involvement: they have variably been reported to have
a similar6
or better22
prognosis when compared to central tumours.
Radiology
Squamous cell
carcinoma is the most frequent type to cavitate. Spiral CT reveals
two to four times as many cancers as does plain chest x-ray18.
CT and MRI have limited sensitivity in the imaging of mediastinal
nodes for staging. FDG-PET gives greater accuracy in assessing both nodes5,18,23
and distant metastases23.
Macroscopic appearances
A
minority of T1 tumours are endobronchial
and exophytic:
they
do not have a better prognosis than other T1N0 squamous carcinomas
of lung8.
Histopathology
There is
keratinisation and/or intercellular bridges are seen.
Variants:
Immunohistochemistry
See
immunohistochemistry of malignant
epithelial tumours of lung.
|
34bE12 |
positive |
|
CK5/6 |
positive13 |
CEA |
positive |
35bH11 |
often positive |
TTF-1 |
usually negative |
CK7 |
usually negative |
Transcription factor E2F1 |
2/1136 |
|
|
|
|
Cytogenetics and
molecular genetics
Numerous somatic
mutations are implicated in the pathogenesis of lung cancer14.
Gains in 3q are more common in squamous carcinomas than in adenocarcinomas15,16,20.
Losses on 3p have also been reported19,20,24.
The FHiT (fragile histidine triad) gene21,34
and RASSF1A26
are two genes on 3p that may be of importance in the pathogenesis of
lung cancer, particularly squamous carcinoma. Certain deletions may
be associated with metastatic potential20.
Epidermal growth factor receptor overexpression is ubiquitous in
squamous cell carcinoma25,
occurs in about 65% of adenocarcinomas and large cell carcinomas but
is not a feature of small cell carcinomas.17
Ultrastructure
Differential diagnosis
-
Large cell carcinoma:
lacks squamous differentiation
-
Adenosquamous
carcinoma may be mimicked by entrapped pneumocytes.
-
Thymic
squamous carcinoma
-
Squamous metaplasia
with atypia in diffuse alveolar damage.
-
Pseudovascular
adenoid squamous cell carcinoma closely mimics angiosarcoma but is
positive for cytokeratins and EMA, negative for CD31, CD34 and Ulex
europaeus I lectin1,2.
Prognosis
-
Stage I five year
survival is 70%.
-
Epidermoid carcinomas
are the non-small cell carcinomas of lung most prone to give rise to
isolated local recurrences7.
-
Basaloid carcinoma is reported to have a prognosis inferior to that
of poorly differentiated squamous cell carcinoma4,12.
-
pRb2/p130 is a member of the retinoblastoma
gene family; loss may correlate with poor overall survival and
is demonstrable by immunohistochemistry28.
Immunohistochemical demonstration of abnormal expression of p27(KIP1)29,
loss of expression of the
fragile histidine triad gene27,34, p1630
or p2133, or overexpression of cyclin E31,32
may predict poor survival. Nuclear, as opposed to cytoplasmic,
expression of the transcription factor Y-box binding protein (YB-1)
correlates with poor prognosis35.
References
Tumours of the Lung, Pleura, Thymus and Heart. WHO Classification of
Tumours. IARC Press 2004.
1
Nappi O, Swanson PE,Wick MR Pseudovascular adenoid squamous cell
carcinoma of the lung: clinicopathologic study of three cases and
comparison with true pleuropulmonary angiosarcoma. Hum Pathol 1994; 25:373-8
2
Ritter JH, Mills SE, Nappi O, et al. Angiosarcoma-like neoplasms of
epithelial organs: true endothelial tumors or variants of carcinoma?
Semin Diagn Pathol 1995; 12:270-82
3
Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma
of the lung: a new morphologic and phenotypic entity with separate
prognostic significance. Hum Pathol 1992; 23:993-1003
4
Moro D, Brichon PY, Brambilla E, et al. Basaloid bronchial carcinoma.
A histologic group with a poor prognosis. Cancer 1994; 73:2734-9
5 Boiselle
PM, Patz EF, Jr., Vining DJ, et al. Imaging of mediastinal lymph
nodes: CT, MR, and FDG PET. Radiographics 1998; 18:1061-9
6 Funai
K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of
peripheral squamous cell carcinoma of the lung. Am J Surg Pathol
2003; 27:978-84
7 Cangemi
V, Volpino P, D'Andrea N, et al. Local and/or distant recurrences in
T1-2/N0-1 non-small cell lung cancer. Eur J Cardiothorac Surg 1995; 9:473-8
8 Dulmet-Brender
E, Jaubert F, Huchon G Exophytic endobronchial epidermoid carcinoma.
Cancer 1986; 57:1358-64
9 Fukino
S, Hayashi E, Fukata T, et al. [Primary clear cell carcinoma of the
lung: report of an operative case]. Kyobu Geka 1998; 51:513-6
10 Katzenstein
AL, Prioleau PG,Askin FB. The histologic spectrum and significance
of clear-cell change in lung carcinoma. Cancer 1980; 45:943-7
11 Churg
A, Johnston WH,Stulbarg M. Small cell squamous and mixed small cell
squamous--small cell anaplastic carcinomas of the lung. Am J Surg
Pathol 1980; 4:255-63
12 Foroulis
CN, Iliadis KH, Mauroudis PM, et al. Basaloid carcinoma, a rare
primary lung neoplasm: report of a case and review of the literature.
Lung Cancer 2002; 35:335-8
13 Chu
PG,Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms:
an immunohistochemical study of 509 cases. Mod Pathol 2002; 15:6-10
14 Balsara
BR,Testa JR Chromosomal imbalances in human lung cancer. Oncogene
2002; 21:6877-83
15 Bjorkqvist
AM, Husgafvel-Pursiainen K, Anttila S, et al. DNA gains in 3q occur
frequently in squamous cell carcinoma of the lung, but not in
adenocarcinoma. Genes Chromosomes Cancer 1998; 22:79-82
16 Chujo
M, Noguchi T, Miura T, et al. Comparative genomic hybridization
analysis detected frequent overrepresentation of chromosome 3q in
squamous cell carcinoma of the lung. Lung Cancer 2002; 38:23-9
17 Franklin
WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor
family in lung cancer and premalignancy. Semin Oncol 2002; 29:3-14
18 Spiro
SG,Porter JC. Lung cancer--where are we today? Current advances in
staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166:1166-96
19 Petersen
I, Bujard M, Petersen S, et al. Patterns of chromosomal imbalances
in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res
1997; 57:2331-5
20 Petersen
S, Aninat-Meyer M, Schluns K, et al. Chromosomal alterations in the
clonal evolution to the metastatic stage of squamous cell carcinomas
of the lung. Br J Cancer 2000; 82:65-73
21 Sozzi
G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung
cancer and preinvasive bronchial lesions. Cancer Res 1998; 58:5032-7
22 Tomashefski
JF, Jr., Connors AF, Jr., Rosenthal ES, et al. Peripheral vs central
squamous cell carcinoma of the lung. A comparison of clinical
features, histopathology, and survival. Arch Pathol Lab Med 1990; 114:468-74
23 Valk
PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer
by whole-body positron emission tomographic imaging. Ann Thorac Surg
1995; 60:1573-81; discussion 1581-2
24 Wistuba,
II, Behrens C, Virmani AK, et al. High resolution chromosome 3p
allelotyping of human lung cancer and preneoplastic/preinvasive
bronchial epithelium reveals multiple, discontinuous sites of 3p
allele loss and three regions of frequent breakpoints. Cancer Res
2000; 60:1949-60
25 Berger
MS, Gullick WJ, Greenfield C, et al. Epidermal growth factor
receptors in lung tumours. J Pathol 1987; 152:297-307
26 Burbee
DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of
RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst 2001; 93:691-9
27 Burke
L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the
FHIT gene predicts poor survival in non-small cell lung cancer.
Cancer Res 1998; 58:2533-6
28 Caputi
M, Groeger AM, Esposito V, et al. Loss of pRb2/p130 expression is
associated with unfavorable clinical outcome in lung cancer. Clin
Cancer Res 2002; 8:3850-6
29 Hirabayashi
H, Ohta M, Tanaka H, et al. Prognostic significance of p27KIP1
expression in resected non-small cell lung cancers: analysis in
combination with expressions of p16INK4A, pRB, and p53. J Surg Oncol
2002; 81:177-84; discussion 184
30 Huang
CI, Taki T, Higashiyama M, et al. p16 protein expression is
associated with a poor prognosis in squamous cell carcinoma of the
lung. Br J Cancer 2000; 82:374-80
31 Mishina
T, Dosaka-Akita H, Hommura F, et al. Cyclin E expression, a
potential prognostic marker for non-small cell lung cancers. Clin
Cancer Res 2000; 6:11-6
32 Muller-Tidow
C, Metzger R, Kugler K, et al. Cyclin E is the only cyclin-dependent
kinase 2-associated cyclin that predicts metastasis and survival in
early stage non-small cell lung cancer. Cancer Res 2001; 61:647-53
33 Shoji
T, Tanaka F, Takata T, et al. Clinical significance of p21
expression in non-small-cell lung cancer. J Clin Oncol 2002; 20:3865-71
34 Tomizawa
Y, Nakajima T, Kohno T, et al. Clinicopathological significance of
Fhit protein expression in stage I non-small cell lung carcinoma.
Cancer Res 1998; 58:5478-83
35 Shibahara
K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding
protein, YB-1, as a novel marker of disease progression in non-small
cell lung cancer. Clin Cancer Res 2001; 7:3151-5
36 Eymin
B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1
expression in human lung tumours: E2F1 is upregulated in small cell
lung carcinoma. Oncogene 2001; 20:1678-87
This page last
revised 14.6.2005.
©SMUHT/PW Bishop